Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects

• Published in: Molecular and cellular endocrinology Vol. 177; no. 1; pp. 35 - 41
• Main Authors: Bollag, R.J, Zhong, Q, Ding, K.H, Phillips, P, Zhong, L, Qin, F, Cranford, J, Mulloy, A.L, Cameron, R, Isales, C.M
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 25-05-2001
• Subjects: Animals; Bone; Bone Density - drug effects; Bone Development - drug effects; Bone mineral density; Disease Models, Animal; Female; Gastric Inhibitory Polypeptide; Gastric Inhibitory Polypeptide - administration & dosage; Gastric Inhibitory Polypeptide - pharmacology; GIP receptor; Humans; Immunoblotting; In Situ Hybridization; Male; Osteoporosis; Osteoporosis - drug therapy; Ovariectomy; Rats; Rats, Sprague-Dawley; Receptors, Gastrointestinal Hormone - genetics; Receptors, Gastrointestinal Hormone - metabolism; RNA, Messenger - metabolism; Tumor Cells, Cultured; Osteoporosis; GIP receptor; Bone mineral density; Bone
• ISSN: 0303-7207; 1872-8057
• DOI: 10.1016/S0303-7207(01)00405-1

Glucose-dependent insulinotropic peptide (GIP) is a gut-derived hormone known to be important in modulating glucose-induced insulin secretion. In addition, GIP receptors are widely distributed and may have effects on multiple other tissues: fat cells, adrenal glands, endothelium and brain. We have demonstrated recently that GIP also has anabolic effects on bone-derived cells. We now demonstrate that GIP administration prevents the bone loss associated with ovariectomy. We propose that GIP plays a unique role in signaling the bone about nutrient availability, indicating the importance of the gut hormones in directing absorbed nutrients to the bone, and suggesting the concept of an ‘entero-osseous axis’. Thus, GIP plays an integrative role helping coordinate efficient and targeted nutrient absorption and distribution.